KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

Pharmacogenomics Journal

Volumn 17, Issue 4, 2017, Pages 360-365

  Rivero Juarez, A ^a   Gonzalez, R ^a   Frias, M ^a   Manzanares Martin B ^a   Rodriguez Cano, D ^a   Perez Camacho, I ^b   Gordon, A ^a   Cuenca, F ^a   Camacho, A ^a   Pineda, J A ^c   Pena J ^d   Rivero, A ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL DE PONIENTE   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; KIR2DS2 PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GENE; GENOTYPING TECHNIQUE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE IL28B CC; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIR2DL1 GENE; KIR2DL2 GENE; KIR2DL3 GENE; KIR2DL4 GENE; KIR2DL5 GENE; KIR2DP1 GENE; KIR2DS1 GENE; KIR2DS2 GENE; KIR2DS3 GENE; KIR2DS4 GENE; KIR2DS5 GENE; KIR3DL1 GENE; KIR3DL2 GENE; KIR3DL3 GENE; KIR3DP1 GENE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS LOAD; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; METABOLISM; PLATELET COUNT; PROCEDURES;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; PLATELET COUNT; RECEPTORS, KIR; RIBAVIRIN; THROMBOCYTOPENIA;

EID: 84961226601     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.19     Document Type: Article

References (31)

1. Platanias LC. Mechanisms of type-I and type-II-interferon mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
2. Lampertico P, Maini M, Papatheodoridis G. Optimal management of Hepatitis B virus infection-EASL Special conference. J Hepatol 2015; 63: 1238-1253.
3. European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C 2014. Available at http://www.easl.eu/-newsroom/latestnews/ easl-recommendations-on-treatment-of-hepatitis-c-2014 last accessed 1 October 2015.
4. Recommendations for Testing, Managing, and Treating Hepatitis C of the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). Available at http://www.hcvguidelines.org last accessed 1 October 2015.
5. Peters van Ton AM, Gevers TJ, Drenth JP. Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 2015; 22: 965-973.
6. Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 2014; 15: 517-526.
7. Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol 2015; 94: 195-207.
8. Ludwig H, Durie BGM, McCarthy P, Palumbo A, San Miguel J, Morgan G et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119: 3003-3015.
9. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD et al. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013; 10: 588-598.
10. Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 2013; 56: 1629-1636.
11. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39: 3-8.
12. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptative immunity? The example of natural killer cells. Science 2011; 331: 44-49.
13. Shifrin N, Raulet DH, Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol 2014; 26: 138-144.
14. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002; 38: 637-660.
15. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection. PLoS Med 2011; 8: e1001092.
16. Rivero-Juarez A, Gonzalez R, Camacho A, Manzanares-Martin B, Caruz A, Martinez-Peinado A et al. Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One 2013; 8: e61992.
17. Vergara S, Macias J, Rivero A, Gutierrez-Valencia A, Gonzalez-Serrano M, Merino D et al. The use of transient elastmetry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969-974.
18. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 1055-1065.
19. Gomez-Lozano N, Vilches C. Genotyping of human killer-cell immunoglobulin-like receptor genes by polymerase chain reaction with sequence-specific primers: an update. Tissue Antigens 2002; 59: 184-193.
20. Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007; 26: 13-19.
21. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
22. Gorelik E, Bere WW, Herberman RB. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984; 33: 87-94.
23. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
24. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
25. Li N. Platelet-lymphocyte cross-talk. J Leukoc Biol 2008; 83: 1069-1078.
26. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010; 67: 499-511.
27. Seymour LA, Nourse JP, Crooks P, Wockner L, Bird R, Tran H et al. The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens 2014; 83: 154-160.
28. Nourse JP, Lea R, Crooks P, Wright G, Tran H, Catalano J et al. The KIR2DS2/2DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis 2012; 23: 45-50.
29. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F et al. Platelet production and destruction in liver cirrhosis. J Hepatol 2011; 54: 894-900.
30. Hernos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K et al. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection. Pharmacoepidemiol Drug Saf 2014; 23: 480-488.
31. Lin KH, Hsu PI, Yu HC, Lin CK, Tsai WL, Chen WC et al. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis C and pretreatment low platelet counts. BMC Gastroenterol 2012; 12: 7.